Potential use of Pichia pastoris strain SMD1168H expressing DNA topoisomerase I in the screening of potential anti‑breast cancer agents
Authors:
Open Access
- 30 April 2019
- journal article
- research article
- Published by Spandidos Publications in Molecular Medicine Reports
- Vol. 19 (6) , 5368-5376
Abstract
Cancer chemotherapy possesses high toxicity, particularly when a higher concentration of drugs is administered to patients. Therefore, searching for more effective compounds to reduce the toxicity of treatments, while still producing similar effects as current chemotherapy regimens, is required. Currently, the search for potential anticancer agents involves a random, inaccurate process with strategic deficits and a lack of specific targets. For this reason, the initial in vitro high‑throughput steps in the screening process should be reviewed for rapid identification of the compounds that may serve as anticancer agents. The present study aimed to investigate the potential use of the Pichia pastoris strain SMD1168H expressing DNA topoisomerase I (SMD1168H‑TOPOI) in a yeast‑based assay for screening potential anticancer agents. The cell density that indicated the growth of the recombinant yeast without treatment was first measured by spectrophotometry. Subsequently, the effects of glutamate (agonist) and camptothecin (antagonist) on the recombinant yeast cell density were investigated using the same approach, and finally, the effect of camptothecin on various cell lines was determined and compared with its effect on recombinant yeast. The current study demonstrated that growth was enhanced in SMD1168H‑TOPOI as compared with that in SMD1168H. Glutamate also enhanced the growth of the SMD1168H; however, the growth effect was not enhanced in SMD1168H‑TOPOI treated with glutamate. By contrast, camptothecin caused only lower cell density and growth throughout the treatment of SMD1168H‑TOPOI. The findings of the current study indicated that SMD1168H‑TOPOI has similar characteristics to MDA‑MB‑231 cells; therefore, it can be used in a yeast‑based assay to screen for more effective compounds that may inhibit the growth of highly metastatic breast cancer cells.Keywords
This publication has 37 references indexed in Scilit:
- Cancer cachexia—pathophysiology and managementJournal of Gastroenterology, 2013
- Yeast-based automated high-throughput screens to identify anti-parasitic lead compoundsOpen Biology, 2013
- New Perspectives on How to Discover Drugs from Herbal Medicines: CAM's Outstanding Contribution to Modern TherapeuticsEvidence-Based Complementary and Alternative Medicine, 2013
- Drug discovery from plant sources: An integrated approachAYU (An International Quarterly Journal of Research in Ayurveda), 2012
- A yeast-based assay identifies drugs active against human mitochondrial disordersProceedings of the National Academy of Sciences, 2011
- Principles of early drug discoveryBritish Journal of Pharmacology, 2011
- New Classes of PDE7 Inhibitors Identified by a Fission Yeast-Based HTSSLAS Discovery, 2010
- Potential Effects of Chrysin on MDA-MB-231 CellsInternational Journal of Molecular Sciences, 2010
- Fed-batch fermentation of GM-CSF-producing glycoengineered Pichia pastoris under controlled specific growth rateMicrobial Cell Factories, 2010
- A yeast-based assay reveals a functional defect of the Q488H polymorphism in human Hsp90αBiochemical and Biophysical Research Communications, 2005